Preview

Колопроктология

Расширенный поиск

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ВЕДОЛИЗУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы)

https://doi.org/10.33878/2073-7556-2017-0-3-71-79

Полный текст:

Об авторе

Андрей Геннадьевич Харитонов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет имени И.И.Мечникова» Министерства здравоохранения Российской Федерации
Россия


Список литературы

1. Molodecky, N.A. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. / N.A.Molodecky, I.S.Soon, D.M.Rabi et al. // Gastroenterology. - 2012; 142 (1): 46-54.

2. Munkholm, P. Intestinal cancer risk and mortality in patients with Crohn’s disease. / P.Munkholm, E.Langholz, M.Davidsen et al. // Gastroenterology. -1993; 105 (6): 1716-23.

3. Dignass, A. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. / A.Dignass, G.Assche, J.O.Lindsay et al. // J. Crohns Colitis. -2010; 4: 28-62.

4. Peyrin-Biroulet, L. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. / L.Peyrin-Biroulet, A.Oussalah, N.Williet et al. // Gut. - 2011; 60 (7): 930-36.

5. Sandborn, W.J. Current directions in IBD therapy: what goals are feasible with biological modifiers? / W.J.Sandborn // Gastroenterology. - 2008; 135 (5): 1442-44.

6. Vester-Andersen, M.K. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. / M.K.Vester-Andersen, M.V.Prosberg, T.Jess // Am. J. Gastroenterol. - 2014; 109 (5): 705-14.

7. Schreiber, S. Maintenance therapy with certolizumab pegol for Crohn’s disease. /S.Schreiber, M.Khaliq-Kareemi, I.C.Lawrance et al. // N. Engl. J. Med. - 2007; 357 (3): 239-50.

8. Hanauer, S.B. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. /S.B.Hanauer, B.G.Feagan, G.R.Lichtenstein et al. // Lancet. - 2002; 359 (9317): 1541-49.

9. Allez, M. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. / M.Allez, K.Karmiris, E.Louis et al. // J. Crohns Colitis. - 2010; 4 (4): 355-66.

10. Hanauer, S.B. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn‘s disease: The Classic-I Trial. / S.B.Hanauer, W.J.Sandborn, P.Rutgeerts et al. // Gastroenterology. - 2006; 130 (2): 323-33.

11. Colombel, J. Adalimumab for maintenance of clinical response and remission in patients with Crohn‘s disease: the charm trial. / J.Colombel, W.J.Sandborn, P.Rutgeerts et al. // Gastroenterology. - 2007; 132 (1): 52-65.

12. Gisbert, J.P. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. / J.P.Gisbert, J.Panés // Am. J. Gastroenterol. - 2009; 104 (3): 760-67.

13. Ben-Horin, S. Review article: loss of response to anti-TNF treatments in Crohn’s disease. / S.Ben-Horin, Y.Chowers // Aliment. Pharmacol. Ther. -2011; 33 (9): 987-95.

14. Gisbert, J.P. Systematic review with metaanalysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. /J.P.Gisbert, A.C.Marin, A.G.McNicholl et al. // Aliment. Pharmacol. Ther. -2015; 41 (7): 613-23.

15. Hoentjen, F. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. /F.Hoentjen, A.A.Bodegraven // World J. Gastroenterol. - 2009; 15 (17): 2067-73.

16. Lichtenstein, G.R. Serious Infection and Mortality in Patients With Crohn’s Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry. /G.R.Lichtenstein, B.G.Feagan, R.D.Cohen // Am. J. Gastroenterol. -2012; 107 (9): 1409-22.

17. Tubach, F. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. / F.Tubach, D.Salmon, P.Ravaud et al. // Arthritis Rheum. - 2009; 60 (7): 1884-94.

18. Stallmach, А. Adverse effects of biologics used for treating IBD. / А.Stallmach, S.Haqel, T.Bruns // Best Pract. Res. Clin. Gastroenterol. - 2010; 24: 167-82.

19. Siegel, C.A. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. / C.A.Siegel, S.M.Marden, S.M.Persing et al. // Clin. Gastroenterol. Hepatol. - 2009; 7 (8): 874-81.

20. Soler, D. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. / D.Soler, T.Chapman, L.L.Yang et al. // J. Pharmacol. Exp.Ther. - 2009; 330 (3): 864-75.

21. Milch, C. Vedolizumab, a monoclonal antibody to the gut homing а4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. / C.Milch, T.Wyant, J.Xu // J. Neuroimmunol. - 2013; 264 (1-2): 123-26.

22. Hesterberg, P.E. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. / P.E.Hesterberg, D.Winsor-Hines, M.J.Briskin et al. // Gastroenterology. - 1996; 111 (5): 1373-80.

23. Feagan, B.G. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. / B.G.Feagan, G.R.Greenberg, G.Wild et al. // Clin. Gastroenterol. Hepatol. - 2008; 6 (12): 1370-77.

24. Sandborn, W.J. Vedolizumab as induction and maintenance therapy for Crohn’s disease. / W.J.Sandborn, B.G.Feagan, P.Rutgeerts et al. //N. Engl. J. Med. - 2013; 369 (8): 711-21.

25. Hanauer, S. Long-term efficacy of vedolizumab therapy for Crohn’s disease. / S.Hanauer, P.Rutgeerts, J.Xu et al. // United Eur. Gastroenterol. J. - 2014;(suppl 1): A66. Abstract 0P205.

26. Sands, B.E. Efficacy and safety of retreatment with vedolizumab in patients with Crohn’s disease. / B.E.Sands, I.Shafran, F.A.Farraye et al. // J. Crohns Colitis. - 2015; 9 (suppl. 1): S. 377.

27. Sands, B.E. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. / B.E.Sands, B.G.Feagan, P.Rutgeerts et al. // Gastroenterology. - 2014; 147 (3): 618-627.

28. Bryant, R.V. Introducing vedolizumab to clinical practice: who, when, and how? / R.V.Bryant, W.J.Sandborn, S.P.Travis // J. Crohns Colitis. - 2015; 9 (4): 356-66.

29. Christensen, B. Vedolizumab in the treatment of IBD: the University of Chicago experience. / B.Christensen, R.G.Sarah, J.C.Ruben et al. // Gastroenterology. - 2015; 148 (4): 866.

30. Shelton, E. Efficacy of vedolizumab as induction therapy in refractory IBD patients. / E.Shelton, J.R.Allegretti, B.Stevens et al. // Inflamm. Bowel Dis. - 2015; 21 (12): 2879-85.

31. Amiot, A. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. / A.Amiot, J.C.Grimaud, L.Peyrin-Biroulet et al. // Clin. Gastroenterol Hepatol. - 2016.

32. Chaudrey, K. Efficacy and safety of vedolizumab for inflammatory bowel disease in clinical practice. / K.Chaudrey, A.Lightner, S.Singh et al. // Inflamm. Bowel Dis. - 2016; 22 (suppl 1): S19-S20. Abstract P033.

33. Vivio, E.E. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. / E.E.Vivio, N.Kanuri, J.J.Gilbertsen et al. // J. Crohns Colitis. - 2016; 10 (4): 402-9.

34. Papamichail, O. Long-term outcome of IBD patients with primary non-response to anti-TNF therapy. / O.Papamichail, O.Rivals, T.Billiet et al. // Gastroenterology. - 2015; 148 (4): S864. Abstract Tu1343.

35. Hanauer, S. Vedolizumab maintenance therapy for Crohn’s disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. / S.Hanauer, J.F.Colombel, F.Beagan et al. // Am. J. Gastroenterol. - 2012; 107 (Suppl. 1): S. 620.

36. Lam, M.C.W. Vedolizumab for induction of remission in Crohn’s disease in adults, a systematic review and meta-analysis. / M.C.W.Lam, N.Fu, B.Bressler et al. // Gastroenterology. - 2015; 148 (4) Suppl. 1: S. 271-272.

37. Colombel, J.F. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. / J.F.Colombel, B.E.Sands, P.Rutgeerts et al. // Gut. - 2016.

38. Scheinfeld, N. A comprehensive review and evaluation of the side-effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. / N.Scheinfeld // J. Dermatolog. Treat. -2004; 15 (5): 280-94.

39. Hochberg, M.C. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. / M.C.Hochberg, M.G.Lebwohl, S.E.Plevy et al. // Semin. Arthritis Rheum. - 2005; 34 (6): 819-36.

40. Hazlewood, G.S. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. / G.S.Hazlewood, A.Rezaie, M.Borman et al. // Gastroenterology. - 2015; 148 (2): 344-54.

41. Magro, F. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). / F.Magro, L.Peyrin-Biroulet, H.Sokol et al. // J. Crohns Colitis. -2014; 8: 31-44.

42. Kappelman, M.D. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. / M.D.Kappelman, D.K.Farkas, M.D.Long et al. // Clin. Gastroenterol. Hepatol. -2014; 12: 265-73.

43. Armuzzi, А. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. / A.Armuzzi, P.Gionchetti, M.Daperno et al. // Dig. Liver Dis. - 2016; 48 (4): 360-70.

44. Colombel, J. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s Disease: The CHARM Trial. / J.Colombel et al. // Gastroenterology. - 2007 132: 52-65.

45. Schreiber, S. Maintenance Therapy with Certolizumab Pegol for Crohn’s Disease / S.Schreiber et al. // N. Engl. J. Med. - 2007 357: 239-25.

46. Hanauer, S.B. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. / S.B.Hanauer et al. // Lancet. - 2002 359 (9317): 1541-154.

47. Инструкция по применению лекарственного препарата для медицинского применения Энтивио®.


Для цитирования:


Харитонов А.Г. ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ВЕДОЛИЗУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы). Колопроктология. 2017;(3):71-79. https://doi.org/10.33878/2073-7556-2017-0-3-71-79

For citation:


Kharitonov A.G. EFFICACY AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE (review). Koloproktologia. 2017;(3):71-79. (In Russ.) https://doi.org/10.33878/2073-7556-2017-0-3-71-79

Просмотров: 133


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)